{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:57:06Z","timestamp":1774634226139,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04893-2","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:49:40Z","timestamp":1773748180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of hepatitis C therapy on urinary outcomes and renal function: a prospective real-world cohort study of early kidney changes"],"prefix":"10.1186","volume":"27","author":[{"given":"Kati","family":"Kaartinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sauli","family":"Vuoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eero","family":"Honkanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliisa","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martti","family":"F\u00c4rkkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"6S","key":"4893_CR1","first-page":"S129","volume":"102","author":"Kidney Disease","year":"2022","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. 2022;102(6S):S129\u2013205.","journal-title":"Kidney Int"},{"issue":"S1","key":"4893_CR2","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.jhep.2016.06.011","volume":"65","author":"P Cacoub","year":"2016","unstructured":"Cacoub P, Desbois A, Isnard-Bagnis C, Rocatello D, Ferri C. Hepatitis C virus infection and chronic kidney disease: time for reappraisal. J Hepatol. 2016;65(S1):S82\u201394.","journal-title":"J Hepatol"},{"key":"4893_CR3","doi-asserted-by":"publisher","unstructured":"Ferri C, Giuggioli D, Colaci M. Renal manifestations of hepatitis C virus. Clin Liver Dis. 2017;21:487\u201397. https:\/\/doi.org\/10.1016\/j.cld.2017.03.005. PMID: 28689588.","DOI":"10.1016\/j.cld.2017.03.005"},{"key":"4893_CR4","doi-asserted-by":"publisher","unstructured":"Rodr\u0131guez-I\u00f1igo E, Casqueiro M, Bartolome\u00b4 J, Barat A, Caramelo C, Ortiz A, et al. Hepatitis C virus RNA in kidney biopsies from infected patients with renal diseases. J Viral Hepat. 2000;7:23\u20139. https:\/\/doi.org\/10.1046\/j.1365-2893.2000.00194.x. PMID: 10718939.","DOI":"10.1046\/j.1365-2893.2000.00194.x"},{"key":"4893_CR5","doi-asserted-by":"publisher","unstructured":"Fabrizi F, Donato MF, Nardelli L, Tripodi F, Zanoni F, Castellano G. Hepatitis C virus infection is associated with proteinuria according to a systematic review with meta-analysis. Nefrologia (Engl Ed). 2024 Jul-Aug;44(4):486\u2013495. https:\/\/doi.org\/10.1016\/j.nefroe.2024.01.021. PMID: 39216980.","DOI":"10.1016\/j.nefroe.2024.01.021"},{"key":"4893_CR6","doi-asserted-by":"publisher","unstructured":"Fabrizi F, Donato FM, Messa P. Association between hepatitis C virus and chronic kidney disease, a systematic review and meta-analysis. Ann. Hepatol. 2018;17:364\u2013391. https:\/\/doi.org\/10.5604\/01.3001.0011.7382 PMID: 29735788.","DOI":"10.5604\/01.3001.0011.7382"},{"key":"4893_CR7","doi-asserted-by":"crossref","unstructured":"Palazzo D, Biliotti E, Tinti F, Bachetoni A, Perinelli P, Cappoli A, et al. Glomerular and tubular kidney involvement in HCV child-a cirrhosis. EASL 2016, poster FRI-164. 2016.","DOI":"10.1016\/j.dld.2015.12.024"},{"key":"4893_CR8","doi-asserted-by":"publisher","unstructured":"Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, Wei L. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis. Nephrol Dial Transplant. 2012;27(2):640-6. https:\/\/doi.org\/10.1093\/ndt\/gfr236. Epub 2011 May 10. PMID: 21558431.","DOI":"10.1093\/ndt\/gfr236"},{"key":"4893_CR9","doi-asserted-by":"publisher","unstructured":"Fabrizi F, Cerutti R, Dixit V, Messa P. The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis. Nefrologia (Engl Ed). 2020 May-Jun;40(3):299\u2013310. English, Spanish. https:\/\/doi.org\/10.1016\/j.nefro.2019.07.007. Epub 2019 Dec 6. PMID: 31813592.","DOI":"10.1016\/j.nefro.2019.07.007"},{"issue":"10","key":"4893_CR10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3748\/wjg.v16.i10.1226","volume":"16","author":"M Derbala","year":"2010","unstructured":"Derbala M, Shebl FM, Rashid A, Amer A, Bener A. Microalbuminuria in hepatitis C-genotype 4: effect of pegylated interferon and ribavirin. World J Gastroenterol. 2010;16(10):1226\u201331. https:\/\/doi.org\/10.3748\/wjg.v16.i10.1226. PMID: 20222166; PMCID: PMC2839175.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4893_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.14672","volume":"41","author":"E Biliotti","year":"2021","unstructured":"Biliotti E, Palazzo DF, D\u2019Alessandro M, Esvan R, Labriola R, Cappoli A, Umbro I, Volpicelli L, Bachetoni A, Villa E, Mitterhofer A, Rucci P, Taliani G. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance. Liver Int. 2021;41(1):158\u201367. https:\/\/doi.org\/10.1111\/liv.14672.","journal-title":"Liver Int"},{"issue":"5","key":"4893_CR12","doi-asserted-by":"publisher","first-page":"e0251392","DOI":"10.1371\/journal.pone.0251392","volume":"16","author":"K Kaartinen","year":"2021","unstructured":"Kaartinen K, Vuoti S, Honkanen E, L\u00f6yttyniemi E, Singh R, F\u00e4rkkil\u00e4 M. Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. PLoS ONE. 2021;16(5):e0251392. https:\/\/doi.org\/10.1371\/journal.pone.0251392.","journal-title":"PLoS ONE"},{"key":"4893_CR13","doi-asserted-by":"publisher","unstructured":"Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption\u2013II. Addiction. 1993;88(6):791\u2013804. https:\/\/doi.org\/10.1111\/j.1360-0443.1993.tb02093.x. PMID: 8329970.","DOI":"10.1111\/j.1360-0443.1993.tb02093.x"},{"key":"4893_CR14","doi-asserted-by":"publisher","unstructured":"Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726\u2009\u2013\u200936. https:\/\/doi.org\/10.1002\/hep.24105. PMID: 21319189.","DOI":"10.1002\/hep.24105"},{"key":"4893_CR15","doi-asserted-by":"publisher","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1114248. PMID: 22762315.","DOI":"10.1056\/NEJMoa1114248"},{"issue":"2","key":"4893_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/ajkd.2002.34487","volume":"40","author":"V Dharnidharka","year":"2002","unstructured":"Dharnidharka V, Kwon C, Stevens G. Serum Cystatin C Is Superior to Serum Creatinine as a Marker of Kidney Function. Am J Kidney Dis. 2002;40(2):221\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4893_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2004.09.025","volume":"38","author":"G Filler","year":"2005","unstructured":"Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A. Cystatin C as a marker of GFR\u2013history, indications, and future research. Clin Biochem. 2005;38(1):1\u20138.","journal-title":"Clin Biochem"},{"issue":"4","key":"4893_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/hep.26556","volume":"59","author":"A Mindikoglu","year":"2014","unstructured":"Mindikoglu A, Dowling T, Weir M, Seliger S, Christenson R, Magder L. Performance of Chronic Kidney Disease Epidemiology Collaboration Creatinine-Cystatin C Equation for Estimating Kidney Function in Cirrhosis. Hepatology. 2014;59(4):1532\u201342.","journal-title":"Hepatology"},{"key":"4893_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12882-015-0188-0","volume":"16","author":"E Krones","year":"2015","unstructured":"Krones E, Fickert P, Zitta S, Neunherz S, Artinger K, Reibnegger G, Durchschein F, Wagner D, Stojakovic T, Stadlbauer V, Fauler G, Stauber R, Zollner G, Kniepeiss D, Rosenkranz A. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol. 2015;16:196. https:\/\/doi.org\/10.1186\/s12882-015-0188-0.","journal-title":"BMC Nephrol"},{"issue":"10","key":"4893_CR20","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.3748\/wjg.v20.i10.2533","volume":"20","author":"N Rognant","year":"2014","unstructured":"Rognant N, Lemoine S. Evaluation of renal function in patients with cirrhosis: where are we now? World J Gastroenterol. 2014;20(10):2533\u201341.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4893_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jvh.13484","volume":"28","author":"Y Tokuchi","year":"2021","unstructured":"Tokuchi Y, Suda G, Kimura M, Maehara O, Kitagataya T, Ohara M, Yamada R, Shigesawa T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. J Viral Hepat. 2021;28(5):755\u201363. https:\/\/doi.org\/10.1111\/jvh.13484.","journal-title":"J Viral Hepat"},{"issue":"1","key":"4893_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","volume":"97","author":"M Sise","year":"2020","unstructured":"Sise M, Chute D, Oppong Y, Davis M, Long J, Silva S, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung R. Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. Kidney Int. 2020;97(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.kint.2019.04.030.","journal-title":"Kidney Int"},{"key":"4893_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.antiviral.2018.10.003","volume":"159","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, Satoh T, Kawano A, Koyanai T, Ooho A, Takahashi K, Kato M, Shimoda S, Kajiwara E, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res. 2018;159:143\u201352. https:\/\/doi.org\/10.1016\/j.antiviral.2018.10.003.","journal-title":"Antiviral Res"},{"issue":"8","key":"4893_CR24","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/hep4.1528","volume":"4","author":"M Sise","year":"2020","unstructured":"Sise M, Strohbehn I, Chute D, Corey K, Fusco D, Sabbisetti V, Waikar S, Chung R. Low Complement C4 Predicts Improvement of Kidney Function After Direct-Acting Antiviral Therapy for Hepatitis C Virus. Hepatol Commun. 2020;4(8):1206\u201317. https:\/\/doi.org\/10.1002\/hep4.1528.","journal-title":"Hepatol Commun"},{"issue":"12","key":"4893_CR25","doi-asserted-by":"publisher","first-page":"e188345","DOI":"10.1172\/JCI188345","volume":"135","author":"D Portilla","year":"2025","unstructured":"Portilla D, Sabapathy V, Chauss D. Role of local complement activation in kidney fibrosis and repair. J Clin Invest. 2025;135(12):e188345. https:\/\/doi.org\/10.1172\/JCI188345. PMID: 40519169; PMCID: PMC12165786.","journal-title":"J Clin Invest"},{"issue":"1","key":"4893_CR26","doi-asserted-by":"publisher","first-page":"e0190146","DOI":"10.1371\/journal.pone.0190146","volume":"13","author":"K Safreed-Harmon","year":"2018","unstructured":"Safreed-Harmon K, Hetherington KL, Aleman S, Alho H, Dalgard O, Frisch T, Gottfredsson M, Weis N, Lazarus JV, Hep-Nordic Study Group. Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. PLoS ONE. 2018;13(1):e0190146. https:\/\/doi.org\/10.1371\/journal.pone.0190146. PMID: 29381697; PMCID: PMC5790214.","journal-title":"PLoS ONE"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04893-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04893-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:04:52Z","timestamp":1774631092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04893-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4893"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04893-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the STROBE statement. The study protocol was approved by the HUS Ethical Committee, decision number HUS\/1264\/2016. All participants gave informed consent before their participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}